NCT06501989 2026-02-11
Study of 5-fluorouracil (5-FU) in Patients With Metastatic Colorectal Cancer
Inova Health Care Services
Phase 2 Withdrawn
Clinical Trials
53 trialsNCT07323576 2026-02-09
INAVO-CRC
Hoffmann-La Roche
Phase 2 Withdrawn
NCT06557278 2025-10-21
COMUNITY
Mirror Biologics, Inc.
Phase 2 Withdrawn
NCT06730100 2025-10-06
CBX-12 for the Treatment of Metastatic Chemotherapy-Refractory Microsatellite Stable Colorectal Cancer
National Cancer Institute (NCI)
Phase 2 Withdrawn
NCT06410534 2025-09-11
A Phase II Study Evaluating an Organ Preservation Strategy Using Immune Checkpoint Blockade for Participants With Primary Colorectal or Gastroesophageal Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Withdrawn
NCT06690281 2025-09-11
A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies
National Institutes of Health Clinical Center (CC)
Phase 2 Withdrawn
NCT06084689 2025-09-02
EMPIRE
Institut Bergonié
Phase 2 Withdrawn
NCT03879811 2025-05-15
Determining the Effects of Temozolomide Followed by Nivolumab in Patients With Colorectal Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Withdrawn
NCT05518032 2024-09-26
Pembrolizumab and Autologous Dendritic Cells for the Treatment of Refractory Colorectal Cancer (CRC)
Roswell Park Cancer Institute
Phase 2 Withdrawn
NCT05356897 2024-09-19
Tucatinib Combined with Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T Study
Academic and Community Cancer Research United
Phase 2 Withdrawn
NCT05690035 2024-07-09
Tislelizumab Combined With Fruquintinib for Metastatic pMMR/MSS Colorectal Cancer
Sun Yat-sen University
Phase 2 Withdrawn
NCT05900648 2024-04-29
Regorafenib and XmAb20717 in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy (RX-CROME)
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT02535988 2023-09-21
Abscopal Effect for Metastatic Colorectal Cancer
Zhejiang Provincial People's Hospital
Phase 2 Withdrawn
NCT05412706 2023-09-08
Bohème
Ospedale Policlinico San Martino
Phase 2 Withdrawn
NCT05582031 2023-06-07
REFIT-MSS
Translational Research in Oncology
Phase 2 Withdrawn
NCT05730673 2023-02-17
Leronlimab in Combination With Regorafenib in Patients With CCR5+, Metastatic Colorectal Cancer
CytoDyn, Inc.
Phase 2 Withdrawn
NCT03982173 2023-01-26
MATILDA
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Withdrawn
NCT00954876 2022-10-20
Study of Capecitabine and Cetuximab as First-Line Therapy in Patients With Metastatic Wild Type Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Colorectal Cancer
Translational Genomics Research Institute
Phase 2 Withdrawn
NCT00936832 2022-08-30
Sunitinib Malate and Combination Chemotherapy as Front-Line Therapy in Treating Patients With Metastatic Rectal Cancer That Cannot Be Removed by Surgery
Federation Francophone de Cancerologie Digestive
Phase 2 Withdrawn
NCT03843853 2022-07-25
Pemetrexed and S-1 in Combination With Bevacizumab in Refractory Colorectal Cancer
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Withdrawn
NCT04119830 2022-02-08
Rintatolimod and Pembrolizumab for the Treatment of Refractory Metastatic or Unresectable Colorectal Cancer
Roswell Park Cancer Institute
Phase 2 Withdrawn
NCT04001101 2021-11-30
Anti-PD-1 +/- RT for MSI-H Solid Tumors
University of Colorado, Denver
Phase 2 Withdrawn
NCT04430985 2021-10-27
IMMUNOX
Herlev Hospital
Phase 2 Withdrawn
NCT01915472 2021-08-19
A Phase II Study of IMMU 130 in Patients With Metastatic Colorectal Cancer
Gilead Sciences
Phase 2 Withdrawn
NCT03524274 2020-10-19
Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Colorectal Cancer
Fuda Cancer Hospital, Guangzhou
Phase 2 Withdrawn
NCT03323424 2020-01-30
IRAM
Institut de Cancérologie de la Loire
Phase 2 Withdrawn
NCT03272659 2019-09-18
PDD
Sir Mortimer B. Davis - Jewish General Hospital
Phase 2 Withdrawn
NCT03340558 2018-10-09
ATELIER
Duke University
Phase 2 Withdrawn
NCT00577109 2018-07-31
A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Previously Untreated Metastatic Colorectal Cancer.
Hoffmann-La Roche
Phase 2 Withdrawn
NCT03222089 2018-03-27
Phase II Trial of FOLFOXIGIL Versus FOLFOXIRI as First-line Therapy in Patients With mCRC
Fujian Cancer Hospital
Phase 2 Withdrawn
NCT00388700 2018-02-14
A New Agent GM-CT-01 in Combination With 5-FU, Avastin and Leucovorin in Subjects With Colorectal Cancer
Galectin Therapeutics Inc.
Phase 2 Withdrawn
NCT03264274 2017-08-31
AUSCOR
Barts & The London NHS Trust
Phase 2 Withdrawn
NCT02345746 2017-08-24
Hepatic Arterial Infusion With FOLFOX Alone or in Combination With IV Chemotherapy in Colon Cancer With Liver Metastasis
Western Regional Medical Center
Phase 2 Withdrawn
NCT02079220 2017-07-31
A Phase II Study of Ziv-aflibercept in Combination With Capecitabine/Oxaliplatin (XELOX) Chemotherapy in the Front-Line Treatment of Patients With Metastatic Colorectal Cancer
University of Pittsburgh
Phase 2 Withdrawn
NCT00002664 2017-07-13
Monoclonal Antibody Therapy and Colony- Stimulating Factor in Treating Patients With Metastatic Colorectal Cancer
George Washington University
Phase 2 Withdrawn
NCT01095523 2017-07-02
Prospective Randomized Trial Evaluating Mandatory Second Look Surgery With HIPEC and CRS vs. Standard of Care in Subjects at High Risk of Developing Colorectal Peritoneal Metastases
National Institutes of Health Clinical Center (CC)
Phase 2 Withdrawn
NCT00408772 2017-06-09
Oxaliplatin, Capecitabine, and Bevacizumab Followed By Surgery and/or Radiofrequency Ablation in Patients With Colorectal Cancer
University of California, Davis
Phase 2 Withdrawn
NCT02413853 2017-04-17
PRIMIER
University of Southern California
Phase 2 Withdrawn
NCT02965417 2017-02-01
Sym004 in Metastatic Colorectal Cancer and ECD-EGFR Patients
Symphogen A/S
Phase 2 Withdrawn
NCT00571740 2016-07-06
Cetuximab and Bevacizumab as First-Line Therapy Followed By Combination Chemotherapy and Bevacizumab With or Without Cetuximab as Second-Line Therapy in Treating Patients With Stage IV Colorectal Cancer
Alliance for Clinical Trials in Oncology
Phase 2 Withdrawn
NCT01157039 2016-02-24
A Trial of Glutamine to Prevent Oxaliplatin Neurotoxicity and a Pharmacokinetic Analysis of Oxaliplatin
AHS Cancer Control Alberta
Phase 2 Withdrawn
NCT01501604 2015-09-17
BKM120 in Cancers With PIK3CA Activating Mutations
Massachusetts General Hospital
Phase 2 Withdrawn
NCT01889680 2014-12-02
Safety and Effectiveness Study of Chemotherapy and Ziv-aflibercept to Treat Metastatic Colorectal Cancer
NSABP Foundation Inc
Phase 2 Withdrawn
NCT00003786 2014-03-07
Irofulven in Treating Patients With Metastatic or Recurrent Colorectal Cancer
University of Chicago
Phase 2 Withdrawn
NCT01293942 2013-06-05
IXO+A in mCRC With Liver-only Metastases
Ottawa Hospital Research Institute
Phase 2 Withdrawn
NCT01540435 2013-05-29
PERIMAX
University of Regensburg
Phase 2 Withdrawn
NCT00118105 2013-01-03
S0408: Capecitabine, Oxaliplatin, and Bevacizumab in Pts Undergoing Surgery for Liver Mets From Colorectal Cancer
SWOG Cancer Research Network
Phase 2 Withdrawn
NCT00766220 2013-01-03
Yttrium Microspheres With Cetuximab Plus Irinotecan for Patients With Advanced Colorectal Cancer Mets to Liver
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT00070434 2012-06-07
S0304 Induct Chemo Then Chemo-RT in Pts w/Locally Advanced Adenocarcinoma of the Rectum
SWOG Cancer Research Network
Phase 2 Withdrawn
NCT01175291 2011-12-05
FOLFOX/Bevacizumab +/- MK-0646 in Metastatic Colorectal Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Withdrawn